StockNews.AI
SONN
StockNews.AI
209 days

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

1. Sonnet's CEO, Pankaj Mohan, will present at a healthcare webinar. 2. The event is scheduled for January 29, 2025, at 2:40 PM ET. 3. Sonnet is focused on immunotherapeutic drugs, targeting ovarian and pancreatic cancers. 4. Sonnet's SON-1010 is in trials with Roche for treating platinum-resistant ovarian cancer. 5. The company has partnered with Alkem for the development of SON-080 in India.

6m saved
Insight
Article

FAQ

Why Bullish?

CEO presentations often boost investor confidence, potentially increasing stock interest. Similar events have historically led to positive stock movements in biotech firms.

How important is it?

CEO's public engagements can enhance visibility and credibility, leading to stock price increases. Events like these are crucial for market engagement in biotech.

Why Short Term?

Immediately following the webinar, we may see short-term investor interest. This aligns with past patterns where investor engagement affects prices rapidly.

Related Companies

ROCHEALKEM
Live webcast on Wednesday, January 29th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief Executive Officer of Sonnet will present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar being held on January 29, 2025. Conference Details: Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Wednesday, January 29, 2025 at 2:40 PM ET Presenter: Pankaj Mohan, Ph.D., Chief Executive Officer Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC (“Webull Financial”), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com. About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines. Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer. The Company’s SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). SON-080 demonstrated encouraging results in a Phase 1b/2a clinical trial, being well tolerated with no evidence of a pro-inflammatory cytokine response. In October 2024, Sonnet announced an India license agreement with Alkem Laboratories, Inc. who will assume responsibility for advancing development of the SON-080 program into a Phase 2 study in DPN. Investor Relations Contact:JTC Team, LLCJenene Thomas 908.824.0775SONN@jtcir.com

Related News